Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 10/20 | 0.45 |
| ▸ | CNR1 | P21554 | 7/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591542 | 0.92 | GLA (0.57) | GLACREBBPMAPK1ALDH1A1 | |
| SCHEMBL3592270 | 0.90 | GLA (0.54) | GLACNR1CREBBPMAPK1ALDH1A1 | |
| SCHEMBL3599312 | 0.87 | GLA (0.53) | GLAMAPK1KDM4EALDH1A1 | |
| SCHEMBL13254019 | 0.87 | GLA (0.75) | GLAMAPK1ALDH1A1 | |
| SCHEMBL3592319 | 0.86 | GLA (0.52) | GLACNR2CNR1MAPK1ALDH1A1 | |
| SCHEMBL3602137 | 0.86 | GLA (0.50) | GLACNR2CNR1CREBBPMAPK1 | |
| SCHEMBL3592685 | 0.84 | GLA (0.49) | GLACREBBPMAPK1ALDH1A1 | |
| SCHEMBL3596804 | 0.81 | GLA (0.54) | GLAMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL3606691 | 0.79 | GLA (0.51) | GLAMAPK1 | |
| SCHEMBL3600671 | 0.76 | PTPN1 (0.47) | GLAMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | GLA 3982/4885CNR2 1364/4885CNR1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.